|
Mathias Svahn
CEO
Halsov 7
Huddinge
Sweden
|
"Mathias Svahn, Ph.D., is the CEO of NextCell Pharma AB, a pioneering biotechnology company specializing in advanced cell therapies. With a doctorate from Karolinska Institutet, Svahn has extensive biotech industry experience and is a serial entrepreneur, serving as a non-executive board member for several advanced therapy companies. He actively contributes to the scientific community through publications and international conferences.
Under his leadership, NextCell Pharma is developing ProTrans, a cell therapy for autoimmune diseases, primarily targeting type 1 diabetes. Phase II data has shown efficacy in preserving insulin production, and the company is preparing for commercialization. ProTrans, developed as an off-the-shelf product, is produced in large batches from multiple donors using a patented selection algorithm, serving as a platform technology for treating inflammatory conditions, including autoimmune diseases.
"
Under his leadership, NextCell Pharma is developing ProTrans, a cell therapy for autoimmune diseases, primarily targeting type 1 diabetes. Phase II data has shown efficacy in preserving insulin production, and the company is preparing for commercialization. ProTrans, developed as an off-the-shelf product, is produced in large batches from multiple donors using a patented selection algorithm, serving as a platform technology for treating inflammatory conditions, including autoimmune diseases.
"